171 related articles for article (PubMed ID: 37289296)
1. Comparison of one-year outcomes between as-needed brolucizumab and aflibercept for polypoidal choroidal vasculopathy.
Fukuda Y; Sakurada Y; Matsubara M; Kotoda Y; Kasai Y; Sugiyama A; Kashiwagi K
Jpn J Ophthalmol; 2023 Jul; 67(4):402-409. PubMed ID: 37289296
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal Brolucizumab and Aflibercept for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kang KH; Yoon W; Lee J; Kim CG; Kim JW
J Ocul Pharmacol Ther; 2023 Nov; 39(9):653-660. PubMed ID: 37504966
[No Abstract] [Full Text] [Related]
3. Comparison of Outcomes between 3 Monthly Brolucizumab and Aflibercept Injections for Polypoidal Choroidal Vasculopathy.
Fukuda Y; Sakurada Y; Matsubara M; Hasebe Y; Sugiyama A; Kikushima W; Kashiwagi K
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572350
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Brolucizumab in Polyp Regression of Treatment-Naive Polypoidal Choroidal Vasculopathy and Its Effect on 1-Year Treatment Outcome.
Lee SH; Park HS; Han JW
Korean J Ophthalmol; 2024 Jun; 38(3):185-193. PubMed ID: 38584441
[TBL] [Abstract][Full Text] [Related]
5. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
6. Switching to brolucizumab from aflibercept in age-related macular degeneration with type 1 macular neovascularization and polypoidal choroidal vasculopathy: an 18-month follow-up study.
Ueda-Consolvo T; Tanigichi A; Numata A; Oiwake T; Nakamura T; Ishida M; Yanagisawa S; Hayashi A
Graefes Arch Clin Exp Ophthalmol; 2023 Feb; 261(2):345-352. PubMed ID: 35947181
[TBL] [Abstract][Full Text] [Related]
7. Short-term efficacy of intravitreal aflibercept for patients with treatment-naïve polypoidal choroidal vasculopathy.
Ijiri S; Sugiyama K
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):351-7. PubMed ID: 25023147
[TBL] [Abstract][Full Text] [Related]
8. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
9. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Hara C; Sawa M; Sayanagi K; Nishida K
Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
Komuku Y; Iwahashi C; Gomi F
Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
[TBL] [Abstract][Full Text] [Related]
11. Association between the arm-to-choroidal circulation time and clinical profile in patients with polypoidal choroidal vasculopathy.
Mukai R; Itagaki K; Honjyo J; Tanaka K; Norikawa K; Sekiryu T
Jpn J Ophthalmol; 2024 May; 68(3):211-215. PubMed ID: 38609716
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy.
Cho HJ; Kim KM; Kim HS; Han JI; Kim CG; Lee TG; Kim JW
Am J Ophthalmol; 2016 May; 165():1-6. PubMed ID: 26921806
[TBL] [Abstract][Full Text] [Related]
13. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
[TBL] [Abstract][Full Text] [Related]
14. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
[TBL] [Abstract][Full Text] [Related]
15. Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy.
Jeong S; Sagong M
Br J Ophthalmol; 2017 Jun; 101(6):758-763. PubMed ID: 27597740
[TBL] [Abstract][Full Text] [Related]
16. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
17. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
[TBL] [Abstract][Full Text] [Related]
18. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
19. Brolucizumab Versus Aflibercept in Participants with Neovascular Age-Related Macular Degeneration: A Randomized Trial.
Dugel PU; Jaffe GJ; Sallstig P; Warburton J; Weichselberger A; Wieland M; Singerman L
Ophthalmology; 2017 Sep; 124(9):1296-1304. PubMed ID: 28551167
[TBL] [Abstract][Full Text] [Related]
20. INTRAVITREAL INJECTION OF AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY: A 3-YEAR FOLLOW-UP.
Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
Retina; 2018 Oct; 38(10):2001-2009. PubMed ID: 28816730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
